GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » PS Ratio

RKVTF (Rakovina Therapeutics) PS Ratio : (As of Apr. 04, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Rakovina Therapeutics's share price is $0.069. Rakovina Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Hence, Rakovina Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Rakovina Therapeutics's PS Ratio or its related term are showing as below:

RKVTF's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.1
* Ranked among companies with meaningful PS Ratio only.

Rakovina Therapeutics's Revenue per Sharefor the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Back to Basics: PS Ratio


Rakovina Therapeutics PS Ratio Historical Data

The historical data trend for Rakovina Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics PS Ratio Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
PS Ratio
- - -

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rakovina Therapeutics's PS Ratio

For the Biotechnology subindustry, Rakovina Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's PS Ratio falls into.


;
;

Rakovina Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Rakovina Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.069/0
=

Rakovina Therapeutics's Share Price of today is $0.069.
Rakovina Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Rakovina Therapeutics  (OTCPK:RKVTF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Rakovina Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics Business Description

Traded in Other Exchanges
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.